By Fineline Cube 
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that its two innovative drugs have been included in the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines. Lisaftoclax (APG-2575), a novel oral Bcl-2 selective inhibitor, and olverembatinib, a next-generation tyrosine kinase inhibitor (TKI), have received significant recognition.
Lisaftoclax: CSCO Guidelines Inclusion
Lisaftoclax has been recommended in the CSCO 2025 Guidelines for the Diagnosis and Treatment of Lymphoid Malignancies. It is the world’s second Bcl-2 inhibitor to submit a New Drug Application (NDA) and the first China-developed Bcl-2 inhibitor to receive Priority Review designation in China. This marks a milestone for Ascentage Pharma and positions lisaftoclax as the only China-developed Bcl-2 inhibitor recommended in the CSCO Guidelines.
Olverembatinib: Upgraded Recommendation
Olverembatinib has received an upgraded recommendation to Level I in the CSCO 2025 Guidelines for the Diagnosis and Treatment of Leukemias in Children and Adolescents. This recognition underscores its effectiveness in treating pediatric Ph+ ALL with the T315I BCR-ABL1 kinase domain mutation. Olverembatinib, jointly commercialized by Ascentage Pharma and Innovent Biologics, holds significant importance in advancing pediatric hematology.-Fineline Info & Tech